(Reuters) -Bristol Myers Squibb will acquire 2seventy bio for about $286 million in cash, sending the cancer cell therapy ...

Multiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird Bio ...

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

CAMBRIDGE, Mass., March 11, 2025--2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under ...

Cambridge: 2seventy bio, Inc. has announced a definitive merger agreement under which Bristol Myers Squibb will acquire all ...

The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly ...

Morgan Stanley lowered the firm’s price target on 2seventy Bio (TSVT) to $5 from $6 and keeps an Equal Weight rating on the shares following ...

Abecma is being jointly developed and commercialized in the U.S. as part of a co-development, co-promotion, and profit share ...

Bio (TSVT) announced a definitive merger agreement under which Bristol Myers Squibb (BMY) will acquire all of the outstanding shares ...

More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling ...

Shares of 2seventy bio took flight Tuesday after the biotechnology company agreed to be acquired by partner Bristol Myers Squibb. Bristol Myers is paying $5 a share in cash for 2seventy, a 79% premium ...

Bristol Myers Squibb is acquiring 2seventy bio, a deal that gives the pharmaceutical giant full control over the partnered cancer cell therapy Abecma as that product faces headwinds in a ...